Skip to main content

Table 5 Comparison of Fatigue and QoL outcomes in mCRPC patients

From: PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

 

HT

(n = 75)

AAP < 3 months (n = 33)

AAP ≥ 3 months (n = 43)

p-value

p-value AAP ≥ 3 months vs AAP < 3 months

p-value

AAP ≥ 3 months vs HT

Fatigue intensity (BFI item 3)

3.0 (0.0–10.0)

4.0 (0.0–8.0)

2.0 (0.0–9.0)

0.125a

0.243

0.043

Fatigue severity, n (%)

   

0.039

No fatigue

15 (20.0)

10 (30.3)

13 (30.2)

Mild fatigue

29 (38.7)

8 (24.2)

19 (44.2)

Moderate fatigue

18 (24.0)

14 (42.4)

9 (20.9)

Severe fatigue

13 (17.3)

1 (3.0)

2 (4.7)

Interference (BFI item 4A-4F)

2.7 (0.0–9.0)

2.7 (0.0–7.0)

1.8 (0.0–10.0)

0.106b

0.473

0.04

FACT-G overall score

77.0 (24.7–101.0)

81.0 (35.0–101.0)

83.0 (38.0–103.0)

0.121c

0.429

0.046

FACT-P overall score

108.3 (50.7–140.0)

114.3 (57.0–137.0)

117.0 (61.0–138.0)

0.052d

0.402

0.018

Physical WB

22.0 (4.0–28.0)

24.0 (12.0–28.0)

24.0 (9.0–28.0)

0.031e

0.643

0.014

Social / Family WB

21.0 (3.0–28.0)

21.0 (2.0–28.0)

20.0 (11.0–28.0)

0.834

Emotional WB

17.0 (3.0–24.0)

17.0 (7.0–23.0)

18.0 (7.0–23.0)

0.727

Functional WB

17.0 (0.0–28.0)

19.0 (3.0–27.0)

21.0 (6.0–28.0)

0.041f

0.054

0.017

Prostate cancer subscale

30.0 (11.0–42.0)

32.0 (17.0–43.0)

34.0 (20.0–43.0)

0.029g

0.462

0.008

  1. Data are expressed as median (IQR), unless otherwise stated
  2. AAP Abiraterone Acetate-prednisone, HT traditional hormone therapy, IQR interquartile range, WB well-being